Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Content from other channels on our network

Permanent identification to follow proven sexual misconduct

Man charged over alleged antisemitic incident in hospital lift

Medical logistics provider gains on-brand hi-vis workwear

Western Sydney Local Health District prosecution withdrawn

Bankstown-Lidcombe and Liverpool Hospitals trial body cameras

EPOC Enviro secures patent for PFAS remediation technology

NSW passes legislation to mandate battery recycling

Climate Council rates political parties on climate

Boral secures grant for cement kiln carbon reduction

Vast secures grant to progress SA Solar Fuels project

Egg producer improves efficiency with flexible marking system

Visy announces new insulation to reduce the use of polystyrene

New liquid catalyst to transform chemical manufacturing

Climate Smart Engineering Conference 2025: program announced

Aussie manufacturing conditions improve at fastest pace since 2022